Latest Industry Insights

In this opinion piece, Liz Sparrow discusses the real risk of the UK losing its science and technology communities as they face a series of challenges that are threatening their growth.

To find out more about how generative artificial intelligence (AI) is helping to accelerate and advance drug discovery processes, we spoke to Dr. Alex Zhavoronkov, CEO of Insilico Medicine.

To learn more about T-cell testing, the types of diseases it can help to diagnose and its value in clinical trials, we spoke to Phill Keefe, chief executive officer of PerkinElmer’s Oxford Immunotec division.

To learn more about the Pioneer Antibody Discovery Platform and its potential impact on drug discovery and development, we spoke to Dr. John Cardone.

This article overviews the science behind the potential use of RRx-001as a “radiation buster” with anti-inflammatory and anti-free radical properties to prevent or reduce both GI-ARS and H-ARS.

We speak with Dr. Niall Martin, CEO of Artios Pharma, to learn more about the development of drugs to target the DNA damage response pathway in cancer.

In this opinion piece, Francois Rieger discusses why reverse mergers are the way forward for advanced therapies.

From increasing trial diversity to using plants to manufacture drugs, the experts weigh in.

To find out more about the Taiwan Precision Medicine Initiative and its aim to implement a sustainable precision health ecosystem in Taiwan, we spoke to Dr. Pui-Yan Kwok, leader of the initiative.

We spoke to Darlene Solomon to learn more about improving sustainability in science and Agilent’s commitment to My Green Lab and other sustainability initiatives.